NICE approves Xeljanz for ulcerative colitis.- Pfizer.
The National Institute for Health and Care Excellence (NICE) has approved Xeljanz (tofacitinib), from Pfizer, for adults with moderate to severe active ulcerative colitis. Xeljanz is part of the class of drugs called Janus kinase (JAK) inhibitors. Currently available treatment often involves infusions or injections, which can be unpleasant and inconvenient for patients. In addition, a number of patients with the condition have found that other treatments such as Remicade (infliximab) or Humira (adalimumab) have failed. Pfizer aims to launch the drug in 2019.
Comment: In August 2018 the European Commission approved treatment consisting of Xeljanz 10 mg twice-daily for at least eight weeks, followed by Xeljanz 5 mg BID or 10 mg, for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins